Prime Medicine Inc. (PRME)
NASDAQ: PRME
· Real-Time Price · USD
3.42
0.08 (2.40%)
At close: Sep 03, 2025, 3:59 PM
2.40% (1D)
| Bid | 3.42 |
| Market Cap | 609.43M |
| Revenue (ttm) | 4.96M |
| Net Income (ttm) | -199.28M |
| EPS (ttm) | -1.56 |
| PE Ratio (ttm) | -2.19 |
| Forward PE | -3.51 |
| Analyst | Hold |
| Ask | 3.46 |
| Volume | 146,621 |
| Avg. Volume (20D) | 4,270,817 |
| Open | 3.40 |
| Previous Close | 3.34 |
| Day's Range | 3.35 - 3.46 |
| 52-Week Range | 1.11 - 5.17 |
| Beta | 2.41 |
About PRME
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PRME
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PRME stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Prime Medicine Inc. is scheduled to release its earnings on
Nov 11, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-4.59%
Prime Medicine shares are trading lower after the ...
Unlock content with
Pro Subscription
1 month ago
+2.35%
Prime Medicine shares are trading lower after the company announced a proposed public offering.
3 weeks ago · fool.com
PRME Revenue Misses by 73%PRME Revenue Misses by 73%
1 month ago · seekingalpha.com
Prime Medicine: Pressing Forward With Lead Liver Targeting IndicationsPrime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds, but is pivoting to larger in-vivo gene editing liver disease targeting opportunities. PRME is priorit...